Novel angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in canine coronary arteries and human platelet aggregation

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 238-246

  Li, Ping ^a   Fukuhara, Masayo ^a   Diz, Debra I ^a   Ferrario, Carlos M ^a   Brosnihan, K Bridget ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ANGIOTENSIN RECEPTOR; CANDESARTAN; IRBESARTAN; LISINOPRIL; PROSTAGLANDIN F2; VALSARTAN;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLOOD VESSEL REACTIVITY; CORONARY ARTERY OBSTRUCTION; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; AUTORADIOGRAPHY; BIPHENYL COMPOUNDS; CORONARY VESSELS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; ISOMETRIC CONTRACTION; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PLATELET AGGREGATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; TETRAZOLES; THROMBOXANE A2; TIME FACTORS; VASOCONSTRICTOR AGENTS;

EID: 0033981547     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. 2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 15:699-703.
2. 2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther 268:747-252.
3. Brunner HR (1997) The new angiotensin II receptor antagonist, Irbesartan: Pharmacokinetic and pharmacodynamic considerations. Am J Hypertension 10:S311-S317.
4. Catalioto RM, Renzetti AR, Criscuoli M, Mizrahi J and Subissi A (1994) Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Eur J Pharmacol 256:93-97.
5. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 265:826-834.
6. Corriu C, Bernard S, Schott C and Stoclet JC (1995) Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 26:688-692.
7. 2 are contractile factors in intrarenal arteries of spontaneously hypertensive rats. Hypertension 19:795-798.
8. 1 receptors. Regul Pept 59:303-311.
9. Goa KL and Wagstaff AJ (1996) Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51: 820-845.
10. 3H]losartan in the rat liver. Biochem Pharmacol 46:1653-1660.
11. Gueraa-Cuesta JI, Monton M, Feo JAR, Jimenez AM, Fernandez FG, Rico LA, Garcia R, Gomez J, Faire J, Casado S and Farre AL (1999) Effect of losartan on human platelet activation. J Hypertension 17:447-452.
12. Hink WF, Romstedt KJ, Burke JW, Doskotch RW and Feller DR (1989) Inhibition of human platelet aggregation and secretion by ant venom and a compound isolated from venom. Inflammation 13:175-184.
13. Jaiswal N, Diz DI, Tallant EA, Khosla MC and Ferrario CM (1991) The non-peptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin release, Am J Hypertension 4:228-233.
14. Lacour C, Canals F, Galindo G, Cazaubon C, Segondy D and Nisato D (1994) Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT, receptor antagonist in hypertensive rat models. Eur J Pharmacol 264:307-316.
15. 2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 281:1065-1070.
16. 2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 32:198-205.
17. Li Z, Bosch SM, Smith TL and Diz DI (1996) Interactions of non-peptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain. J Cardiovasc Pharmacol 28:425-431.
18. 2-mediated mechanism of vascular contraction in hypertensive rats: Relation to lipoxygenase and prostacyclin synthase activities. Circ Res 74:197-205.
19. 2 (TP) receptors. Prostaglandins 44:89-99.
20. Maeso R, Navarro J, Munoz-Garcia R, Rodrigo E, Ruilope LM, Lahera V and Cachofeiro V (1995) Losartan but not captopril reduces catecholamine constrictor response in aortic rings from SHR (Abstract). Hypertension 25:52.
21. 2 analogue in aortic rings from spontaneously hypertensive rats: Role of nitric oxide. J Hypertension 15:1677-1684.
22. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D and Ferrario CM (1994) Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 266:R1273-R1278.
23. Ogletree ML, Harris DN, Greenberg R, Haslanger MF and Nakane M (1985) Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 234:435-441.
24. Ohlstein EH, Gellai M, Brooks DP, Vickery L, Jugus J, Sulpizio A, Ruffolo RR Jr, Weinstock J and Edwards RM (1992) The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther 262:595-601.
25. 3 receptors in the conscious rat. Br J Pharmacol 114: 1563-1570.
26. Pool JL, Guthrie RM, Littlejohn TW III, Raskin P, Shephard AMM, Weber MA, Weir MR, Wilson TW, Wright J, Kassler-Taub KB and Reeves RA (1998) Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertension 11:462-470.
27. Reeves RA, Lin CS, Kassler-Taub K and Pouleur H (1998) Dose-related efficacy of irbesartan for hypertension: An integrated analysis. Hypertension 31:1311-1316.
28. Ruilope LM (1997) Renoprotection and renin-angiotensin system blockade in diabetes mellitus. Am J Hypertension 10:S325-S331.
29. Sachinidis A, Ko Y, Weisser P, Meyer ZU Brickwedde M-K, Dusing R, Christian R, Wieczorek AJ and Vetter H (1993) EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertension 11:155-162.
30. Schafer AI (1996) Antiplatelet therapy. Am J Med 101:199-209.
31. 2 receptors in human platelets, rat vascular endothelial cells and rat vascular smooth muscle cells. J Pharmacol Exp Ther 267:1017-1023.
32. 2 and prostacyclin in the pathogenesis of coronary vasospasm and thrombosis. Adv Prostaglandin Thromboxane Leukot Res 15:481-484.
33. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JM and Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251.
34. 1-receptor antagonist losartan in hypertension. J New Dev Clin Med 13:195-206.
35. Verstraete M (1995) New developments in antiplatelet and antithrombotic therapy. Eur Heart J 16:16-23.
36. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD and Timmermans PBMWM (1996) Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy. J Med Chem 39:625-656.
37. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL and Timmermans PBMWM (1990) Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, and orally active antihypertensive agent. J Pharmacol Exp Ther 255:211-217.
38. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL and Timmermans PBMWM (1990) Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 15:459-468.